Virchow to make Sputnik V vaccine in India

Virchow to make Sputnik V vaccine in India
x

Virchow to make Sputnik V vaccine in India 

Highlights

Moscow: The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Virchow Biotech Private Ltd, a part of the Virchow Group and one...

Moscow: The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Virchow Biotech Private Ltd, a part of the Virchow Group and one of the leading vaccine and pharmaceutical producers in India, have entered into an agreement to produce 200 million doses per year of Sputnik V in India. Sputnik V is the world's first registered vaccine against coronavirus.

The technology transfer is expected to be completed in the second quarter of 2021 followed by full-scale commercial production of Sputnik V.

Virchow Biotech capacities will help facilitate global supply of Sputnik V to international partners of RDIF. Sputnik V has been registered in 54 countries globally with total population of over 1.4 billion people.

Efficacy of Sputnik V is 91.6 per cent as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

Show Full Article
Print Article
Interested in blogging for thehansindia.com? We will be happy to have you on board as a blogger.
Next Story
More Stories